Hallmarks of cancer: Interactions with the tumor stroma

Experimental Cell Research

Volumn 316, Issue 8, 2010, Pages 1324-1331

  Pietras, Kristian ^a   Östman, Arne ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cancer; Cancer associated fibroblast; Pericyte; Targeted therapy; Tumor stroma

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL COMMUNICATION; CELL INTERACTION; DRUG MECHANISM; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; LEUKOCYTE; MALIGNANT NEOPLASTIC DISEASE; MESENCHYME CELL; METASTASIS; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STROMA; ANIMAL; GENETICS; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION; STROMA CELL;

ANIMALS; FIBROBLASTS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 77952568396     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.02.045     Document Type: Review

References (72)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
2. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6:392-401.
3. Ostman A., Augsten M. Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr. Opin. Genet. Dev. 2009, 19:67-73.
4. Sugimoto H., Mundel T.M., Kieran M.W., Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol. Ther. 2006, 5:1640-1646.
5. Anderberg C., Li H., Fredriksson L., Andrae J., Betsholtz C., Li X., Eriksson U., Pietras K. Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res. 2009, 69:369-378.
6. Anderberg C., Pietras K. On the origin of cancer-associated fibroblasts. Cell Cycle 2009, 8:1461-1462.
7. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., Richardson A.L., Polyak K., Tubo R., Weinberg R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
8. Camps J.L., Chang S.M., Hsu T.C., Freeman M.R., Hong S.J., Zhau H.E., von Eschenbach A.C., Chung L.W. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc. Natl. Acad. Sci. USA 1990, 87:75-79.
9. Morikawa S., Baluk P., Kaidoh T., Haskell A., Jain R.K., McDonald D.M. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 2002, 160:985-1000.
10. Gaengel K., Genove G., Armulik A., Betsholtz C. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 2009, 29:630-638.
11. Abramsson A., Lindblom P., Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J. Clin. Invest. 2003, 112:1142-1151.
12. Song S., Ewald A.J., Stallcup W., Werb Z., Bergers G. PDGFRbeta+perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat. Cell Biol. 2005, 7:870-879.
13. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337.
14. Demehri S., Kopan R. Notch signaling in bulge stem cells is not required for selection of hair follicle fate. Development 2009, 136:891-896.
15. Bhowmick N.A., Chytil A., Plieth D., Gorska A.E., Dumont N., Shappell S., Washington M.K., Neilson E.G., Moses H.L. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004, 303:848-851.
16. Valin A., Barnay-Verdier S., Robert T., Ripoche H., Brellier F., Chevallier-Lagente O., Avril M.F., Magnaldo T. PTCH1 +/- dermal fibroblasts isolated from healthy skin of Gorlin syndrome patients exhibit features of carcinoma associated fibroblasts. PLoS ONE 2009, 4:e4818.
17. Kiaris H., Chatzistamou I., Trimis G., Frangou-Plemmenou M., Pafiti-Kondi A., Kalofoutis A. Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Res. 2005, 65:1627-1630.
18. Hill R., Song Y., Cardiff R.D., Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2005, 123:1001-1011.
19. Trimboli A.J., Cantemir-Stone C.Z., Li F., Wallace J.A., Merchant A., Creasap N., Thompson J.C., Caserta E., Wang H., Chong J.L., Naidu S., Wei G., Sharma S.M., Stephens J.A., Fernandez S.A., Gurcan M.N., Weinstein M.B., Barsky S.H., Yee L., Rosol T.J., Stromberg P.C., Robinson M.L., Pepin F., Hallett M., Park M., Ostrowski M.C., Leone G. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 2009, 461:1084-1091.
20. Strnad H., Lacina L., Kolar M., Cada Z., Vlcek C., Dvorankova B., Betka J., Plzak J., Chovanec M., Sachova J., Valach J., Urbanova M., Smetana K. Head and neck squamous cancer stromal fibroblasts produce growth factors influencing phenotype of normal human keratinocytes. Histochem. Cell Biol. 2010, 133:201-211.
21. LeBedis C., Chen K., Fallavollita L., Boutros T., Brodt P. Peripheral lymph node stromal cells can promote growth and tumorigenicity of breast carcinoma cells through the release of IGF-I and EGF. Int. J. Cancer 2002, 100:2-8.
22. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F., Csiszar K., Giaccia A., Weninger W., Yamauchi M., Gasser D.L., Weaver V.M. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
23. Thijssen V.L., Brandwijk R.J., Dings R.P., Griffioen A.W. Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Exp. Cell Res. 2004, 299:286-293.
24. Fukumura D., Xavier R., Sugiura T., Chen Y., Park E.C., Lu N., Selig M., Nielsen G., Taksir T., Jain R.K., Seed B. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998, 94:715-725.
25. Amano H., Hayashi I., Endo H., Kitasato H., Yamashina S., Maruyama T., Kobayashi M., Satoh K., Narita M., Sugimoto Y., Murata T., Yoshimura H., Narumiya S., Majima M. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J. Exp. Med. 2003, 197:221-232.
26. Williams C.S., Tsujii M., Reese J., Dey S.K., DuBois R.N. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 2000, 105:1589-1594.
27. Ikeda Y., Hayashi I., Kamoshita E., Yamazaki A., Endo H., Ishihara K., Yamashina S., Tsutsumi Y., Matsubara H., Majima M. Host stromal bradykinin B2 receptor signaling facilitates tumor-associated angiogenesis and tumor growth. Cancer Res. 2004, 64:5178-5185.
28. Pietras K., Pahler J., Bergers G., Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 2008, 5:e19.
29. Augsten M., Hagglof C., Olsson E., Stolz C., Tsagozis P., Levchenko T., Frederick M.J., Borg A., Micke P., Egevad L., Ostman A. CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc. Natl. Acad. Sci. USA 2009, 106:3414-3419.
30. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., Carey V.J., Richardson A.L., Weinberg R.A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
31. Furuhashi M., Sjoblom T., Abramsson A., Ellingsen J., Micke P., Li H., Bergsten-Folestad E., Eriksson U., Heuchel R., Betsholtz C., Heldin C.H., Ostman A. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res. 2004, 64:2725-2733.
32. Robinson S.P., Ludwig C., Paulsson J., Ostman A. The effects of tumor-derived platelet-derived growth factor on vascular morphology and function in vivo revealed by susceptibility MRI. Int. J. Cancer 2008, 122:1548-1556.
33. McCarty M.F., Somcio R.J., Stoeltzing O., Wey J., Fan F., Liu W., Bucana C., Ellis L.M. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J. Clin. Invest. 2007, 117:2114-2122.
34. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
35. Sung S.Y., Hsieh C.L., Law A., Zhau H.E., Pathak S., Multani A.S., Lim S., Coleman I.M., Wu L.C., Figg W.D., Dahut W.L., Nelson P., Lee J.K., Amin M.B., Lyles R., Johnstone P.A., Marshall F.F., Chung L.W. Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res. 2008, 68:9996-10003.
36. Xian X., Hakansson J., Stahlberg A., Lindblom P., Betsholtz C., Gerhardt H., Semb H. Pericytes limit tumor cell metastasis. J. Clin. Invest. 2006, 116:642-651.
37. Finak G., Bertos N., Pepin F., Sadekova S., Souleimanova M., Zhao H., Chen H., Omeroglu G., Meterissian S., Omeroglu A., Hallett M., Park M. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 2008, 14:518-527.
38. Farmer P., Bonnefoi H., Anderle P., Cameron D., Wirapati P., Becette V., Andre S., Piccart M., Campone M., Brain E., Macgrogan G., Petit T., Jassem J., Bibeau F., Blot E., Bogaerts J., Aguet M., Bergh J., Iggo R., Delorenzi M. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 2009, 15:68-74.
39. Crawford Y., Kasman I., Yu L., Zhong C., Wu X., Modrusan Z., Kaminker J., Ferrara N. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009, 15:21-34.
40. Wang W., Li Q., Yamada T., Matsumoto K., Matsumoto I., Oda M., Watanabe G., Kayano Y., Nishioka Y., Sone S., Yano S. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin. Cancer Res. 2009, 15:6630-6638.
41. Pietras K., Ostman A., Sjoquist M., Buchdunger E., Reed R.K., Heldin C.H., Rubin K. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001, 61:2929-2934.
42. Pietras K., Rubin K., Sjöblom T., Buchdunger E., Sjöquist M., Heldin C.-H., Östman A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 2002, 62:5476-5484.
43. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., Frese K.K., Denicola G., Feig C., Combs C., Winter S.P., Ireland-Zecchini H., Reichelt S., Howat W.J., Chang A., Dhara M., Wang L., Ruckert F., Grutzmann R., Pilarsky C., Izeradjene K., Hingorani S.R., Huang P., Davies S.E., Plunkett W., Egorin M., Hruban R.H., Whitebread N., McGovern K., Adams J., Iacobuzio-Donahue C., Griffiths J., Tuveson D.A. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
44. Yauch R.L., Gould S.E., Scales S.J., Tang T., Tian H., Ahn C.P., Marshall D., Fu L., Januario T., Kallop D., Nannini-Pepe M., Kotkow K., Marsters J.C., Rubin L.L., de Sauvage F.J. A paracrine requirement for hedgehog signalling in cancer. Nature 2008, 455:406-410.
45. Santos A.M., Jung J., Aziz N., Kissil J.L., Pure E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J. Clin. Invest. 2009, 119:3613-3625.
46. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 2003, 111:1287-1295.
47. Erber R., Thurnher A., Katsen A.D., Groth G., Kerger H., Hammes H.P., Menger M.D., Ullrich A., Vajkoczy P. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004, 18:338-340.
48. Pietras K., Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol. 2005, 23:939-952.
49. Tsujino T., Seshimo I., Yamamoto H., Ngan C.Y., Ezumi K., Takemasa I., Ikeda M., Sekimoto M., Matsuura N., Monden M. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin. Cancer Res. 2007, 13:2082-2090.
50. Paulsson J., Sjoblom T., Micke P., Ponten F., Landberg G., Heldin C.H., Bergh J., Brennan D.J., Jirstrom K., Ostman A. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am. J. Pathol. 2009, 175:334-341.
51. Infante J.R., Matsubayashi H., Sato N., Tonascia J., Klein A.P., Riall T.A., Yeo C., Iacobuzio-Donahue C., Goggins M. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J. Clin. Oncol. 2007, 25:319-325.
52. Jarvius M., Paulsson J., Weibrecht I., Leuchowius K.J., Andersson A.C., Wahlby C., Gullberg M., Botling J., Sjoblom T., Markova B., Ostman A., Landegren U., Soderberg O. In situ detection of phosphorylated platelet-derived growth factor receptor beta using a generalized proximity ligation method. Mol. Cell. Proteomics 2007, 6:1500-1509.
53. R.A. Saito, P. Micke, P. Jönsson, J. Botling, K. Edlund, L. Johansson, P. Carlsson, K. Jirström, K. Miyazono, A. Östman. FoxF1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer, Cancer Res. (in press). doi:10.1158/0008-5472.CAN-09-3644.
54. Hasumi Y., Klosowska-Wardega A., Furuhashi M., Ostman A., Heldin C.H., Hellberg C. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int. J. Cancer 2007, 121:2606-2614.
55. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
56. Crisan M., Yap S., Casteilla L., Chen C.W., Corselli M., Park T.S., Andriolo G., Sun B., Zheng B., Zhang L., Norotte C., Teng P.N., Traas J., Schugar R., Deasy B.M., Badylak S., Buhring H.J., Giacobino J.P., Lazzari L., Huard J., Peault B. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008, 3:301-313.
57. Paquet-Fifield S., Schluter H., Li A., Aitken T., Gangatirkar P., Blashki D., Koelmeyer R., Pouliot N., Palatsides M., Ellis S., Brouard N., Zannettino A., Saunders N., Thompson N., Li J., Kaur P. A role for pericytes as microenvironmental regulators of human skin tissue regeneration. J. Clin. Invest. 2009, 119:2795-2806.
58. Pietras A., Gisselsson D., Ora I., Noguera R., Beckman S., Navarro S., Pahlman S. High levels of HIF-2alpha highlight an immature neural crest-like neuroblastoma cell cohort located in a perivascular niche. J. Pathol. 2008, 214:482-488.
59. Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., Oh E.Y., Gaber M.W., Finklestein D., Allen M., Frank A., Bayazitov I.T., Zakharenko S.S., Gajjar A., Davidoff A., Gilbertson R.J. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
60. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
61. Erez N., Truitt M., Olson P., Hanahan D. Cancer Associated Fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-KB-dependent manner. Cancer Cell 2010, 17(2):135-147.
62. Boersma B.J., Reimers M., Yi M., Ludwig J.A., Luke B.T., Stephens R.M., Yfantis H.G., Lee D.H., Weinstein J.N., Ambs S. A stromal gene signature associated with inflammatory breast cancer. Int. J. Cancer 2008, 122:1324-1332.
63. Liao D., Luo Y., Markowitz D., Xiang R., Reisfeld R.A. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE 2009, 4:e7965.
64. Balsamo M., Scordamaglia F., Pietra G., Manzini C., Cantoni C., Boitano M., Queirolo P., Vermi W., Facchetti F., Moretta A., Moretta L., Mingari M.C., Vitale M. Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc. Natl. Acad. Sci. USA 2009, 106(49):20847-20852.
65. Grum-Schwensen B., Klingelhofer J., Grigorian M., Almholt K., Nielsen B.S., Lukanidin E., Ambartsumian N. Lung Metastasis Fails in MMTV-PyMT Oncomice Lacking S100A4 Due to a T-Cell Deficiency in Primary Tumors. Cancer Res. 2010, 70(3):936-947.
66. Hamzah J., Jugold M., Kiessling F., Rigby P., Manzur M., Marti H.H., Rabie T., Kaden S., Grone H.J., Hammerling G.J., Arnold B., Ganss R. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008, 453:410-414.
67. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., MacDonald D.D., Jin D.K., Shido K., Kerns S.A., Zhu Z., Hicklin D., Wu Y., Port J.L., Altorki N., Port E.R., Ruggero D., Shmelkov S.V., Jensen K.K., Rafii S., Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-827.
68. Erler J.T., Bennewith K.L., Cox T.R., Lang G., Bird D., Koong A., Le Q.T., Giaccia A.J. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009, 15:35-44.
69. McAllister S.S., Gifford A.M., Greiner A.L., Kelleher S.P., Saelzler M.P., Ince T.A., Reinhardt F., Harris L.N., Hylander B.L., Repasky E.A., Weinberg R.A. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008, 133:994-1005.
70. Wadlow R.C., Wittner B.S., Finley S.A., Bergquist H., Upadhyay R., Finn S., Loda M., Mahmood U., Ramaswamy S. Systems-level modeling of cancer-fibroblast interaction. PLoS ONE 2009, 4:e6888.
71. Abe Y., Oda-Sato E., Tobiume K., Kawauchi K., Taya Y., Okamoto K., Oren M., Tanaka N. Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2. Proc. Natl. Acad. Sci. USA 2008, 105:4838-4843.
72. Ponten F., Jirstrom K., Uhlen M. The Human Protein Atlas-a tool for pathology. J. Pathol. 2008, 216:387-393.